Cytokinetics | CYTK - Ebitda

Stock Price
75.85
Daily Change
-2.79 -3.55%
Monthly
15.94%
Yearly
144.68%
Q2 Forecast
74.33

Cytokinetics reported $-169.32M in EBITDA for its fiscal quarter ending in March of 2026.





Ebitda Change Date
Acadia Pharmaceuticals USD 20.31M 15.44M Dec/2025
Amgen USD 5.14B 775M Dec/2025
Arca Biopharma USD -25.07M 5.23M Mar/2025
Bayer EUR 4.45B 2.49B Mar/2026
Biogen USD 649.7M 76.5M Mar/2026
Brainstorm Cell Therapeutics USD -3.04M 99K Mar/2025
Bristol-Myers Squibb USD 2.88B 1.36B Dec/2025
Capricor Therapeutics USD -27.23M 2.66M Jun/2025
Cytokinetics USD -169.32M 19.48M Mar/2026
Eisai JPY 30.1B 6.62B Dec/2025
Eli Lilly USD 12.14B 4.26B Dec/2025
Exelixis USD 258.29M 15.43M Mar/2026
Geron USD -21.29M 11.82M Dec/2025
Halozyme Therapeutics USD 21.9M 226.34M Dec/2025
Ionis Pharmaceuticals USD -200.02M 42.89M Dec/2025
Ligand Pharmaceuticals USD 66.78M 83.54M Dec/2025
Merck USD 6.3B 2.09B Dec/2025
Novartis USD 5.3B 530M Mar/2026
Pfizer USD 5.99B 5.23B Mar/2026
Regeneron Pharmaceuticals USD 1.2B 718.4M Dec/2025
Roche Holding CHF 12.68B 2.36B Jun/2024
Sanofi EUR 3.31B 3.65B Mar/2026